Advertisement

Topics

International Therapeutics Incorporated Company Profile

00:40 EST 22nd November 2017 | BioPortfolio

International Therapeutics, Inc. (ITI) is developing a novel anti-viral technology called Nuclear Importation Inhibition (NII) that may be applied against chronic viral disease such as HIV-1, hepatitis B (HBV), and herpes viruses. The technology is the subject of eight issued US patents and a series of foreign filings.

The Company, started in 1999, has set up offices and laboratories in Seattle to test its proprietary compounds using in vitro assays for cellular toxicity and anti-viral activity. ITI is currently in pre-clinical testing of a number of compounds with demonstrated in vitro activities against HIV-1. The lead compound ITI-011 is orally bio-available, with a promising in vitro toxicity profile. Continued development of ITI-011 for animal PK and toxicity is underway. ITI anticipates filing an IND for clinical evaluation of ITI-011 in Phase I human studies, in 2002.



ITI is also pursuing a drug discovery program to identify additional small molecule inhibitors of HIV-1, HBV, and herpes viruses.

Location

600 Broadway Medical
Seattle
Washington
98122
United States of America

Contact

Phone: 206-329-3563
Fax: 206-329-3919
Email: bmacpherson@internationaltherapeutics.com


News Articles [647 Associated News Articles listed on BioPortfolio]

Vical Incorporated Announces Pricing of $25 Million Underwritten Public Offering of Common Stock

SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the pricing of its underwritten public offering of 14,285,714 shares of common stock or common stock ...

Mersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of anti...

Concurrent with BMS acquisition, IFM Therapeutics spins off IFM Therapeutics LLC

Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC.

International conference on molecular targets & cancer therapeutics to be Held Oct. 26-30

(American Association for Cancer Research) The American Association for Cancer Research (AACR), the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer (EORTC...

Amicus Therapeutics nets $243.2mm in FOPO

Amicus Therapeutics Inc. (small-molecule therapeutics for rare and orphan diseases) netted $243.2mm in a follow-on public offering of 21.1mm common shares (including the overallotment) at $12.25. The...

Grid Therapeutics closes Series A round

Grid Therapeutics LLC (oncology) raised an undisclosed sum in its Series A round, which included investments from lead backer Longview International and Duke University.

Cerenis Therapeutics: Completion of Patient Enrollment in the Phase 3 Study, TANGO, Evaluating CER-001 in HDL Genetic Deficiency

Regulatory News: Cerenis Therapeutics (FR0012616852 CEREN PEA PME eligible) (Paris:CEREN) an international biopharmaceutical company dedicated to the discovery and development of innovative therap...

Cerenis Therapeutics Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City, September 10-12, 201

Regulatory News: Cerenis Therapeutics (FR0012616852 CEREN PEA PME eligible) (Paris:CEREN), an international biopharmaceutical company dedicated to the discovery and development of innovative thera...

Clinical Trials [936 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [2466 Associated Companies listed on BioPortfolio]

PRAECIS PHARMACEUTICALS INCORPORATED

PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...

CNS Therapeutics

Founded in 2007 by recognized experts in intrathecal drug therapies, CNS Therapeutics is a private company based in St. Paul, Minnesota. CNS Therapeutics develops and markets safe...

Garmin

Garmin International Inc. is a subsidiary of Garmin Ltd. (Nasdaq: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United State...

Convergent Therapeutics

Convergent Therapeutics acquires, certifies and distributes specialty pharmaceuticals, prescription drugs and drug/device combinations prescribed or used by specialty physicians in Canada and select i...

LAB International Inc.

LAB International (LAB Pharma and LAB Research) is an integrated drug development company with subsidiaries focused on developing and manufacturing novel therapeutics for the multi-billion dollar inha...

More Information about "International Therapeutics Incorporated" on BioPortfolio

We have published hundreds of International Therapeutics Incorporated news stories on BioPortfolio along with dozens of International Therapeutics Incorporated Clinical Trials and PubMed Articles about International Therapeutics Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of International Therapeutics Incorporated Companies in our database. You can also find out about relevant International Therapeutics Incorporated Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

AIDS and HIV
AIDS; Acquired Immune Deficiency Syndrome. HIV; Human Immunodeficiency Virus HIV infection causes AIDS. HIV infection also causes the production of anti-HIV antibodies, which forms the test for HIV in patients. People who have the HIV antibodies are ...


Corporate Database Quicklinks



Searches Linking to this Company Record